Fig. 5From: Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cellsThe venetoclax and ATO combination downregulates Mcl-1 through GSK-3β activation in KG1 and KG1a cells. a–c, Representative western blot analysis of the indicated proteins in KG1 and KG1a cells treated with venetoclax (200 nM), ATO (3 µM), or both in combination for 48 h. Similar results were obtained from three independent experimentsBack to article page